肝内胆管癌——国内外专家共识及指南解读

doi:10.16139/j.1007-9610.2021.02.008

摘要/Abstract

中图分类号:

R735.8

王冲, 程石. 肝内胆管癌——国内外专家共识及指南解读[J]. 外科理论与实践, 2021, 26(02): 124-129.

WANG Chong, CHENG Shi. Intrahepatic cholangiocarcinoma: interpretation of expert consensus and guideline from domestic and abroad[J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 124-129.

参考文献 33

[1]	Aloia T, Pawlik TM, Taouli B, et al. Cancer Staging Ma-nual[M]. 8th edition. New York: Springer, 2017:295-302.
[2]	Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer, 2020, 126(11):2666-2678.
[3]	Chun YS, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3):1073274817729241.
[4]	Weber SM, Ribero D, O′Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8):669-680.
[5]	国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗—外科专家共识[J]. 临床肝胆病杂志, 2015(1):12-16.
[6]	胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
[7]	National Comprehensive Cancer Network. Hepatobiliary Cancers, Version 5[J/OL]. 2020-08-04. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[8]	科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略”专家组. 肝内胆管癌外科治疗中国专家共识(2020版)[J]. 中华消化外科杂志, 2021, 20(1):1-15.
[9]	Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma[J]. Surg Endosc, 2006, 20(5):721-725. pmid: 16508808
[10]	Nakanuma Y, Curado MP, Franceschi S, et al. Intrahe-patic cholangiocarcinoma[M]. 4th edition.Lyon: IARC Press, 2010:217-222.
[11]	Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiolo-gical, clinicopathological, and molecular features[J]. Mod Pathol, 2014, 27(8):1163-1173.
[12]	Krasinskas AM. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018, 11(2):403-429. doi: S1875-9181(18)30005-9 pmid: 29751883
[13]	Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2017, 115(6):696-703. doi: 10.1002/jso.24569 pmid: 28194791
[14]	Kang SH, Hwang S, Lee YJ, et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(4):240-248.
[15]	Yamamoto Y, Sugiura T, Okamura Y, et al. The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: a proposal of a modified new staging system[J]. J Gastrointest Surg, 2020, 24(4):786-795. doi: 10.1007/s11605-019-04185-1 pmid: 31012045
[16]	Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9):1188-1195.
[17]	董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011版)[J]. 中华消化外科杂志, 2011, 10(1):20-25.
[18]	中华医学会数字医学分会, 中国医师协会肝癌专业委员会, 中国医师协会精准医学专业委员会, 等. 原发性肝癌三维可视化技术操作及诊疗规范(2020版)[J]. 中国实用外科杂志, 2020, 40(9):991-1011.
[19]	Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(12):4020-4028. doi: 10.1245/s10434-015-4472-9 pmid: 25762481
[20]	Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: a multicenter study[J]. Surgery, 2019, 166(6):975-982.
[21]	程石, 王冲. 肝内胆管细胞癌的外科治疗策略[J]. 国际外科学杂志, 2020, 47(6):365-368.
[22]	Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188. doi: 10.1002/hep.28744 pmid: 27481548
[23]	Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2012, 28(3):258-265.
[24]	Sahai P, Kumar S. External radiotherapy and brachythe-rapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence[J]. Br J Radiol, 2017, 90(1076):20170061.
[25]	Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer[J]. Br J Surg, 2018, 105(3):192-202. doi: 10.1002/bjs.10776 pmid: 29405274
[26]	Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673. doi: S1470-2045(18)30915-X pmid: 30922733
[27]	Mizusawa J, Morizane C, Okusaka T, et al. Randomized Phase Ⅲ study of gemcitabine plus S-1 versus gem-citabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study(JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4):385-388. doi: 10.1093/jjco/hyv213 pmid: 27025903
[28]	Phelip JM, Vendrely V, Rostain F, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phaseⅡ randomised study[J]. Eur J Cancer, 2014, 50(17):2975-2982.
[29]	Jackson MW, Amini A, Jones BL, et al. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma[J]. Cancer J, 2016, 22(4):237-242.
[30]	Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
[31]	Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metasta-tic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5):671-684. doi: S1470-2045(20)30109-1 pmid: 32203698
[32]	Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2):213-220.
[33]	Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1):235-243. doi: 10.1245/s10434-015-4642-9 pmid: 26059651

肝内胆管癌——国内外专家共识及指南解读

Intrahepatic cholangiocarcinoma: interpretation of expert consensus and guideline from domestic and abroad

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
[2]	陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.
[3]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[4]	尹彦江, 罗治文, 陈晓, 张业繁, 黄振, 赵宏, 赵建军, 李智宇, 周健国, 蔡建强, 毕新宇. 肝内胆管癌病人肝脏手术切缘与预后的关系[J]. 外科理论与实践, 2022, 27(03): 221-228.
[5]	陈承坤综述, 郭伯敏, 邓先兆, 伍波, 樊友本审校. 甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(03): 276-280.
[6]	刘深洋, 汤朝晖, 全志伟. 肝内胆管癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 100-106.
[7]	方诚, 夏勇, 王葵, 沈锋. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27(02): 107-112.
[8]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[9]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[10]	杨建军, 宋致成, 顾岩. 肥胖合并食管裂孔疝的外科治疗策略[J]. 外科理论与实践, 2021, 26(05): 394-398.
[11]	刘红枝, 林自国, 黄建龙, 周伟平, 程张军, 楼健颖, 郑树国, 毕新宇, 王剑明, 郭伟, 李富宇, 王坚, 郑亚民, 李敬东, 程石, 刘景丰, 曾永毅. 切缘宽度对单发肝内胆管癌预后影响的多中心研究[J]. 外科理论与实践, 2021, 26(02): 130-137.
[12]	司安锋, 雷正清, 杨平华, 江涛, 王轩, 程张军. 巨块型肝内胆管癌术后经肝动脉化疗栓塞的有效性[J]. 外科理论与实践, 2021, 26(02): 138-143.
[13]	余莉,. 脓胸的治疗原则及进展[J]. 内科理论与实践, 2020, 15(01): 21-24.
[14]	沈宇辉. 规范癌症骨转移的外科治疗[J]. 外科理论与实践, 2019, 24(05): 417-420.
[15]	吴峻立, 苗毅. 慢性胰腺炎的外科诊治现状[J]. 外科理论与实践, 2019, 24(03): 194-198.